This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 08
  • /
  • NICE again rejects Nexavar (sorafenib) as a Treatm...
Drug news

NICE again rejects Nexavar (sorafenib) as a Treatment for liver cancer.-Bayer

Read time: 1 mins
Last updated: 21st Aug 2016
Published: 21st Aug 2016
Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) is re-appraising the drugs which until now were provided under the UK Cancer Drugs Fund (CDF). In 2010 NICE had rejected Nexavar (sorafenib) for the treatment of liver cancer but the drug became available under the CDF. NICE considers that there is uncertainty about the overall survival benefit of Nexavar for liver cancer patients and does not recommend it.

Doctor holding patients hand in consultation
Doctor holding patients hand in consultation
Learning Zone

Supportive Care in Oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Read more
How do you prefer to access medical updates and information?
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Blue test tubes arranged in a line, disappearing into the background
Drug news
Moderna reports H5 Flu data
Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.
Read more
Drug news
Cibotercept in PAH ends

Published: 30th May 2025

Read more
Drug news
Khindivi cleared for pediatrics

Published: 30th May 2025

Read more
See all news